Sequential follow-up of serum thyroglobulin and whole body scan in thyroid cancer patients without initial metastasis

Thyroid

Volumn 16, Issue 12, 2006, Pages 1273-1278

  Huang, Shu Hua ^a   Wang, Pei Wen ^a,b   Huang, Yu Erh ^a   Chou, Fong Fu ^a   Liu, Rue Tsuan ^a   Tung, Shih Chen ^a   Chen, Jung Fu ^a   Kuo, Ming Chun ^a   Hsieh, Jing Rong ^a   Hsieh, Hsin Hung ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; THYROGLOBULIN; THYROXINE;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CELL DIFFERENTIATION; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; WHOLE BODY IMAGING;

ADULT; AGED; CARCINOMA, PAPILLARY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; SUBSTANCE WITHDRAWAL SYNDROME; THYROGLOBULIN; THYROID NEOPLASMS; THYROXINE; WHOLE BODY IMAGING;

EID: 33846149990     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2006.16.1273     Document Type: Article

References (29)

1. Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP, Fragu P, Lumbroso J, Caillou B, Parmentier C 1986 Long-term results of treatment of 283 patients with lung and bone metastases form differentiated thyroid carcinoma. J Clin Endocrinol Metab 63:960-967.
2. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS 1993 Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050-1058.
3. Pacini F, Cetani F, Miccoli P, Mancusi F, Ceccarelli C, Lippi F, Martino E, Pinchera A 1994 Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J Surg 18:600-604.
4. Mazzaferri EL, Kloos RT 2001 Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86:1447-1463.
5. Pacini F, Pinchera A, Giani C, Grasso L, Baschieri L 1980 Serum thyroglobulin concentration and I-131 whole body scans in the diagnosis of metastases from differentiated thyroid carcinoma (after thyroidectomy). Clin Endocrinol (Oxf) 13:107-110.
6. Schlumberger M, Baudin E 1998 Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol 138:249-252.
7. Cailleux AF, Baudin E, Travagli JP, Richard M, Schlumberger M 2000 Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 85:175-178.
8. Mazzaferri EL, Kloos RT 2002 Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 87:1490-1498.
9. Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT 2002 Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid 12:37-43.
10. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A 2003 Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88:3668-3673.
11. Torre EM, Carballo MTL, Erdozain RMR, Llenas LF, Iriarte MJG, Layana JJB 2004 Prognostic value of thyroglobulin serum levels and 1-131 whole body scan after initial treatment of low-risk differentiated thyroid cancer. Thyroid 14:301-306.
12. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Pacini F, Reiners C, Franco FS, Toft A, Wiersinga WM 2004 Follow-up of low-risk patients with differentiated thyroid carcinoma: A European perspective. Eur J Endocrinol 150:105-112.
13. Kloos RT, Mazzaferri EL 2005 A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 90:5047-5057.
14. Pacini F, Molinaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C, Taddei D, Elisei R, Capezzone M, Pinchera A 2001 Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 86:5686-5690.
15. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Landenson PW, Pinchera A 2003 A consencus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88:1433-1441.
16. Sisson JC, Thompson NW, Giordano TJ, England BG, Normolle DP 2000 Serum thyroglobulin levels after thyroxine withdrawal in patients with low risk papillary thyroid carcinoma. Thyoid 10:165-169.
17. Baudin E, Cao CD, Cailleux AF, Lebouleux S, Travagli JP, Schlumberger M 2003 Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 88:1107-1111.
18. Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, Molinaro E, Pinchera A 2001 Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic I-131 whole body scan: Comparison of patients treated with high 1-131 activities versus untreated patients. J Clin Endocrinol Metab 86:4092-4097.
19. Mazzaferri EL, Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428.
20. Pacini F, Lippi F, Formica N, Elisei R, Anelli S, Ceccarelli C, Pinchera A 1987 Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 28:1888-1891.
21. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A 2002 Diagnostic 131-iodine whole body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 87:1499-1501.
22. Grigsby PW, Baglan K, Siegel BA 1999 Surveillance of patients to detect recurrent thyroid carcinoma. Cancer 85:945-951.
23. Westbury C, Vini L, Fisher C, Harmer C 2000 Recurrent differentiated thyroid cancer without elevation of serum thyroglobulin. Thyroid 10:171-176.
24. Brendel AJ, Lambert B, Guyot M, Jeandot R, Dubourg H, Roger P, Wynchauk S, Manciet G, Lefort G 1990 Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma. Eur J Nucl Med 16:35-38.
25. Schlumberger M 1998 Papillary and follicular thyroid cancer. N Engl J Med 338:297-306.
26. Goretzki PE, Simon D, Frilling A, Witte J, Reiners C, Grussendorf M, Horster FA, Roher HD 1993 Surgical reintervention for differentiated thyroid carcinoma. Br J Surg 80:1009-1012.
27. Ericsson UB, Tegler L, Lennquist S, Stahl E, Thorell JI 1984 Serum thyroglobulin in differentiated thyroid carcinoma. Acta Chir Scand 150:367-375.
28. Ronga G, Filesi M, Ventroni G, Vestri AR, Signore A 1999 Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma. Eur J Nucl Med 26:1448-1452.
29. Bachelot A, Cailleux AF, Klain M, Baudin E, Ricard M, Bellon N, Caillou B, Travagli JP, Schlumberger M 2002 Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid 12:707-711.